vxb-241
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 13, 2024 (NCT06556147)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human metapneumovirusImmunity, active
Human metapneumovirus immunity, active
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06556147 | Phase 1 | Aug 13, 2024 | Sunshine Coast University, Australia, Veritas Research., Corp., Vicebio |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Coast University, Australia | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Veritas Research., Corp. | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Vicebio | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1